Condition: Gastrointestinal Neoplasms · Sponsor: GlaxoSmithKline
The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug named sunitinib. The study will see if IDRX-42 works well and is safe for participants whose GIST has spread or cannot be surgically removed, and who have already taken the drug imatinib. Participants whose disease worsens after receiving sunitinib in this study may cross over to receive GSK6042981, at investigator's discretion and if additional eligibility criteria are met.
This description comes directly from the study's public registry record.
US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Phoenix, Arizona, United States | Recruiting |
| GSK Investigational Site | La Jolla, California, United States | Recruiting |
| GSK Investigational Site | Los Angeles, California, United States | Recruiting |
| GSK Investigational Site | San Francisco, California, United States | Recruiting |
| GSK Investigational Site | New Haven, Connecticut, United States | Recruiting |
| GSK Investigational Site | Jacksonville, Florida, United States | Recruiting |
| GSK Investigational Site | Miami, Florida, United States | Recruiting |
| GSK Investigational Site | Orlando, Florida, United States | Recruiting |
| GSK Investigational Site | Tampa, Florida, United States | Recruiting |
| GSK Investigational Site | Iowa City, Iowa, United States | Recruiting |
| GSK Investigational Site | Overland Park, Kansas, United States | Recruiting |
| GSK Investigational Site | Boston, Massachusetts, United States | Recruiting |
+ 112 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07218926